Related Experiment Video
Updated: Feb 7, 2026
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
Published on: June 30, 2017
Erlotinib
Martin Steins1, Michael Thomas2, Michael Geißler3
1Clinic for Thoracic Diseases, University of Heidelberg, Röntgenstr. 1, 69126, Heidelberg, Germany. martin.steins@med.uni-heidelberg.de.
Abstract:
The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of which are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.
Insights
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, like erlotinib, show efficacy in treating cancers such as non-small cell lung and pancreatic cancer. Clinical data highlight their applications, effectiveness, and toxicity, alongside predictive response markers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) signaling is crucial in cancer development, regulating proliferation, migration, and survival.
- EGFR's tyrosine kinase activity is a key driver of tumor progression and a significant therapeutic target.
Purpose of the Study:
- To review clinical data on EGFR tyrosine kinase inhibitors, focusing on erlotinib.
- To discuss the efficacy, toxicity, and predictive markers for erlotinib in various cancers, especially non-small cell lung and pancreatic cancer.
Main Methods:
- Review of clinical trial data and scientific literature on EGFR tyrosine kinase inhibitors.
- Analysis of erlotinib's clinical applications, efficacy, and safety profiles.
Main Results:
- EGFR tyrosine kinase inhibitors have demonstrated significant efficacy in clinical settings.
- Erlotinib is an approved small molecule inhibitor with established clinical applications.
- Predictive markers for treatment response are crucial for optimizing patient outcomes.
Conclusions:
- EGFR tyrosine kinase inhibition represents a valuable therapeutic strategy in oncology.
- Further research into predictive markers will enhance the personalized application of EGFR inhibitors like erlotinib.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
08:35Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
Published on: August 24, 2018